Kansas City, KSNCT06744647Now EnrollingIRB Ready

Antibody-Mediated Rejection Clinical Trial in Kansas City, KS

Access cutting-edge antibody-mediated rejection treatment through this clinical trial at a research site in Kansas City. Study-provided care at no cost to qualified participants.

Sponsored by Alexion Pharmaceuticals, Inc.

Quick Self-Assessment

See if you qualify for this Kansas City location

Preparing your pre-screening questions…

Expert Care in Kansas City

Access antibody-mediated rejection specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related antibody-mediated rejection treatment provided free

Apply for This Kansas City Location

Check if you qualify for this antibody-mediated rejection clinical trial in Kansas City, KS

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Kansas City

    Convenient for KS residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Kansas City site if eligible
  4. 4Begin participation

About This Antibody-Mediated Rejection Study in Kansas City

The primary objective of this study is to evaluate the efficacy of ALXN2030 compared with placebo on biopsy proven histologic resolution in participants with active or chronic active antibody-mediated rejection (AMR) at Week 52.

Sponsor: Alexion Pharmaceuticals, Inc.

Who Can Participate

Inclusion Criteria

Kidney transplant received ≥ 6 months
Active or chronic active AMR according to Banff 2022 classification, based on Screening kidney biopsy
Either positive C4d on Screening kidney biopsy based on the Central Pathology Laboratory report and/or positive HLA Class I and/or II antigen-specific DSA as determined by the local laboratory's definition of positivity using single-antigen bead based assays
MVI score ≥ 2 (g ≥ 1 and ptc ≥ 1)
eGFR ≥ 30 mL/min/1.73 m2
Must be vaccinated against meningococcal infection from serogroups A, C, W, Y (and B where available) at least 14 days prior to but no more than 3 years prior to Day 1
Must be vaccinated for S pneumoniae prior to randomization
Must be vaccinated for H influenzae type B (where available) prior to randomization
Body weight ≥ 50 kg at Screening

Exclusion Criteria

Biopsy-based diagnosis of any of the following at Screening:
TCMR, according to the Banff grade ≥ 1
Polyoma virus nephropathy
Severe thrombotic microangiopathy
Glomerulonephritis
ABO-incompatible transplant
uACR \> 2200 mg/g
Multiorgan transplant recipient (except for previous multiple kidney transplants) or cell transplant (islet, bone marrow, stem cell) recipient
Planned or recent treatments, \< 90 days prior to the Screening Visit and during Screening, for Acute Rejection, AMR (including plasmapheresis, plasma exchange, IVIg, B-cell depleting therapy, IL inhibitors, proteasome inhibitors, high-dose corticosteroids \[except for tapering\]), HDS products with known hepatotoxic ingredients, TCMR (including T-cell depleting therapy), excluding the SoC immunosuppressant treatment which will be allowed and should be stable during the entire treatment.
Known medical or psychological condition, including substance abuse or use disorder (including alcohol), or risk factor that may interfere with study participation, pose additional risk, or confound study outcomes

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Kansas City?

Yes, this clinical trial (NCT06744647) has an active research site in Kansas City, KS that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Antibody-Mediated Rejection Treatment Options in Kansas City, KS

If you're searching for antibody-mediated rejection treatment options in Kansas City, KS, this clinical trial (NCT06744647) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Kansas City research site is actively enrolling participants for this clinical trial. You'll receive care from experienced antibody-mediated rejection specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all antibody-mediated rejection clinical trials near you to find additional studies recruiting in your area.

More Erectile Dysfunction Trials in Kansas City, KS

See all erectile dysfunction clinical trials recruiting in Kansas City — not just this study.

Browse Erectile Dysfunction Trials in Kansas City →

Browse More Trials by Condition

Erectile Dysfunction TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in Kansas City?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Kansas City, KS